LIVMOR receives FDA clearance for the world's first prescriptible wearable for continuous heart monitoring
Availability of physician-prescribed cardiac monitoring system will significantly improve screening and treatment of atrial fibrillation and other chronic heart conditions.
DALLAS, Oct. 15, 2020 /PRNewswire/ -- LIVMOR, Inc., a leading digital health solutions company, announced today that the Company received FDA 510(k) clearance for the LIVMOR Halo™ AF Detection System, a physician-prescribed wearable solution that provides continuous monitoring of pulse rhythms for the detection of atrial fibrillation (AF), on demand during the day and automatically overnight. Continuous monitoring can significantly enhance the detection of paroxysmal (intermittent) or asymptomatic forms of AF. The LIVMOR Halo™ System, deployed on a Samsung wearable*, can be worn daily, and because it is completely non-invasive (no incisions, medical adhesives or electrodes) the patient's pulse rhythms recorded by the device can be analyzed for AF indefinitely.
LIVMOR receives FDA clearance for the world’s first prescriptible wearable for continuous heart monitoring. In a multi-center clinical trial with 269 enrolled patients, the LIVMOR Halo(TM) was 100% sensitive in identifying patients with AF and 93% specific in identifying patients without AF.
A multi-center clinical trial was conducted with 269 enrolled patients, comparing the accuracy of the LIVMOR Halo™ System, in the processing of photoplethysmogram (PPG) signals recorded by the Samsung wearable, with a concurrently recorded electrocardiogram (ECG), currently the gold-standard for measuring heart rhythms. The ECG recordings were reviewed for accuracy by automated algorithms, ECG technicians, and cardiologists, and were subsequently compared to the concurrently recorded pulse rhythms from the LIVMOR Halo™ system. The LIVMOR Halo™ was 100% sensitive in identifying patients with AF and 93% specific in identifying patients without AF.
AF is the most common form of abnormal heart rhythm among US adults with prevalence increasing substantially with age, affecting 9% of US adults over 65.1 AF significantly increases risk of stroke, heart failure and vascular dementia, making early detection critical to prevent disease progression and life-threatening health consequences.2 Unfortunately, as many as half of patients with AF have no symptoms and are unaware of their significant health risks.3
Dr. Subhash Banerjee, Chief of Cardiology, North Texas VA, Co-principal Investigator: "The goal of LIVMOR's AF detection monitor is to provide cost-effective systemic population monitoring for patients susceptible to having atrial fibrillation, particularly those with paroxysmal or asymptomatic forms of AF and also for those with a prior diagnosis of AF, to provide clinically valuable monitoring for the management of the condition."
Ken Persen, Founder & CEO, LIVMOR: "The FDA 510(k) clearance of our LIVMOR Halo™ AF detection system (deployed as an integrated part of the LIVMOR Halo+™ Home Monitoring system powered by Samsung) is a significant milestone for LIVMOR and serves as a foundational cornerstone in our Samsung-based digital health platform. Starting today, medical professionals across the US can prescribe our LIVMOR Halo™, a patient-engaging and extendable system, for their at-risk patients. This is major step toward achieving our vision of a transformative patient-provider ecosystem that more proactively prevents, detects, and manages chronic conditions."
Taher Behbehani, GM & Head of Mobile B2B, Samsung Electronics America: "With the increased need for remote care and monitoring, Samsung is committed to working with strategic partners to develop innovative digital health solutions. We are thrilled that LIVMOR's secure AF detection monitor on Samsung wearables has achieved this significant milestone, helping clinicians reach even more patients with potentially lifesaving technology."
About LIVMOR
Founded in 2016, LIVMOR is a leading digital health solutions company whose mission is to assist physicians and medical professionals in addressing the global chronic disease epidemic by providing a patient-engaging remote monitoring system of critical physiological biomarkers. LIVMOR's goals are to dramatically improve patient outcomes and to significantly reduce healthcare system costs with better quality data for diagnosis and treatment of chronic diseases. For more information visit www.livmor.com, or engage with LIVMOR on LinkedIn.
1. Camm AJ, Corbucci G, Padeletti L. Usefulness of continuous electrocardiographic monitoring for atrial fibrillation. Am J Cardiol. 2012 Jul 15;110(2):270-6. doi: 10.1016 / j.amjcard. 2012.03.021. Epub 2012 Apr 12.
2. Sumeet S. Chugh, Rasmus Havmoeller, Kumar Narayanan, David Singh, Michiel Rienstra, Emelia J. Benjamin, Richard F. Gillum, Young-Hoon Kim, John H. McAnulty Jr, Zhi-Jie Zheng, et al. Worldwide Epidemiology of Atrial Fibrillation A Global Burden of Disease 2010 Study. 17 Dec 2013 Circulation. 2014;129: 837–847
3. Rienstra M, Vermond RA, Crijns HJ, et al. Asymptomatic persistent atrial fibrillation and outcome: results of the RACE study. Heart Rhythm. 2014;11(6):939-945.
* The LIVMOR AF detection system is FDA cleared class-II medical device software. It is powered by the LIVMOR Halo +™ home monitoring system, an FDA registered medical solution that is provided to the patients pre-loaded and validated on a Samsung Gear S2 with an integrated PPG monitor. Samsung Gear S2 are not FDA cleared for the detection of Atrial Fibrillation in the absence of LIVMOR controls.
Share this article